ctDNA in Cancer Treatment and Clinical Care: Workshop Agenda

Check-in starts at 8:15 AM for both days. Note that all guests to NCI Shady Grove campus are required to go through visitor security screening; please allow enough time to pass through security and check-in to the workshop before the start of the event. All times are listed in Eastern Daylight Time.

Day 1: September 14, 2023

Day 1. September 14,	2025	
Welcome and Opening	<u>Remarks</u>	
9:00 AM - 9:15 AM	Welcome and workshop format	Dr. Brian Sorg
9:15 AM - 9:30 AM	Workshop overview	Dr. Lyndsay Harris
Statistician and Patient	Perspectives on ctDNA	
	ctDNA clinical trial designs	Dr. Lisa McShane
9:45 AM - 10:00 AM	Patient perspective on ctDNA in treatment management and care	Patty Spears
10:00 AM - 10:15 AM	Discussion	
10:15 AM - 10:30 AM		
	t of Solid Tumors in the Neoadjuvant Setting	
10:30 AM - 10:45 AM	Perioperative ctDNA dynamics with hepatectomy for colorectal liver metastases	Dr. Arvind Dasari
10:45 AM - 11:00 AM	ctDNA to detect residual disease after neoadjuvant therapy in breast cancer	Dr. Muhammed Murtaza
11:00 AM - 11:15 AM	ctDNA in neoadjuvant-treated breast cancer reflects response and survival	Dr. Laura van 't Veer
11:15 AM - 11:30 AM	Discussion	
ctDNA for Managemen	t of Solid Tumors in the Adjuvant Setting	
11:30 AM - 11:45 AM	ctDNA kinetics predict PFS and OS in EGFR TKI-treated patients with EGFR-Mutant NSCLC	Dr. Philip Mack
11:45 AM - 12:00 PM	ctDNA guiding adjuvant therapy in colon cancer	Dr. Yuxuan Wang
12:00 PM - 12:15 PM	Plasma ctDNA response is an early marker of treatment effect in advanced NSCLC	Dr. Yanan Kuang
12:15 PM - 12:30 PM	Discussion	
12:30 PM - 1:30 PM	Lunch	
ctDNA Post-Treatment	and MRD Surveillance of Solid Tumors	
1:30 PM - 1:45 PM		Dr. Heather Parsons
1:45 PM - 2:00 PM	MRD detection using plasma-only ctDNA in patients with colorectal cancer	Dr. Aparna Parikh
2:00 PM - 2:15 PM	ctDNA for MRD for treatment monitoring in advanced melanoma patients	Dr. Zeynep Eroglu
2:15 PM - 2:30 PM	·	
	f Metastatic Solid Tumors	
2:30 PM - 2:45 PM	ctDNA serial analysis during progression on PD-1	Dr. Pashtoon M. Kasi
2:45 PM - 3:00 PM	Longitudinal ctDNA-based model associated with survival in metastatic NSCLC	Dr. Katja Schulze
3:00 PM - 3:15 PM	Evolution of the genomic landscape of ctDNA in metastatic prostate cancer over treatment and time	Dr. Pedro Barata
3:15 PM - 3:30 PM	Discussion	
3:30 PM - 3:45 PM	Break	
Challenges of ctDNA as		
3:45 PM - 4:00 PM	Biological/technical challenges in collection/analysis of cfDNA	Dr. Abhijit Patel
4:00 PM - 4:15 PM	ctDNA pre-analytical variables and best practices for sample collection	Dr. Sarah Greytak
4:15 PM - 4:30 PM	Evaluating the analytical validity of ctDNA sequencing assays for precision oncology	Dr. Joshua Xu
4:30 PM - 4:45 PM	Economic value of liquid biopsy for genomic profiling in advanced NSCLC	Dr. Doreen A. Ezeife
4:45 PM - 5:00 PM	Discussion	
5:00 PM - 5:15 PM	Announcements/Day 1 Wrap-Up, Adjourn	
	, , , , , , , , , , , , , , , , , , ,	

ctDNA in Cancer Treatment and Clinical Care: Workshop Agenda

Check-in starts at 8:15 AM for both days. Note that all guests to NCI Shady Grove campus are required to go through visitor security screening; please allow enough time to pass through security and check-in to the workshop before the start of the event. All times are listed in Eastern Daylight Time.

Day 2: September 15, 2023

Day 2. September 13, 2023			
Welcome/Announcements			
NCI Funding Initiatives for ctDNA Projects			
NOFOs for ctDNA support	Dr. Miguel Ossandon		
Beyond DNA Mutations and Blood			
HBV viral-host junction DNA in urine as a biomarker for HCC MRD and recurrence	Dr. Ying-Hsiu Su		
ctDNA in saliva for treatment and monitoring	Dr. David Wong		
Methylated microRNA biomarkers in saliva of head and neck cancer recurrence	Dr. Shi-Long Lu		
Collection, analysis, and clinical use of ctDNA in CSF	Dr. Alexandra Miller		
Discussion			
Break			
Genomic profiling of bronchoalveolar lavage cfDNA in lung cancer	Dr. Viswam Nair		
Methylated cfDNA for disease subtyping and prognostics	Dr. Scott Bratman		
DNA methylation signatures of retinoblastoma using aqueous humor liquid biopsy	Dr. Jesse Berry		
ctDNA in urine to detect MRD and predict survival in bladder cancer	Dr. Aadel Chaudhuri		
Discussion			
Lunch			
Advances in Technology, Assays, and Clinical Translation			
ctDNA and other technological advances	Dr. Chris Karlovich		
Advancing clinical applications for liquid biopsy for FGFR-positive cancers	Dr. Sameek Roychowdhury		
Regulatory considerations for ctDNA assays	Dr. Liz Mansfield		
BloodPAC protocols for analytical validation of ctDNA assays	Dr. Jennifer Dickey		
Discussion			
Wrap-up, Adjourn			
	for ctDNA Projects NOFOs for ctDNA support and Blood HBV viral-host junction DNA in urine as a biomarker for HCC MRD and recurrence ctDNA in saliva for treatment and monitoring Methylated microRNA biomarkers in saliva of head and neck cancer recurrence Collection, analysis, and clinical use of ctDNA in CSF Discussion Break Genomic profiling of bronchoalveolar lavage cfDNA in lung cancer Methylated cfDNA for disease subtyping and prognostics DNA methylation signatures of retinoblastoma using aqueous humor liquid biopsy ctDNA in urine to detect MRD and predict survival in bladder cancer Discussion Lunch y, Assays, and Clinical Translation ctDNA and other technological advances Advancing clinical applications for liquid biopsy for FGFR-positive cancers Regulatory considerations for ctDNA assays BloodPAC protocols for analytical validation of ctDNA assays Discussion		